Should I Buy PAVM? PAVM 2026 Analysis

Should You Buy PAVmed Inc (PAVM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.640

1 Day change

-5.91%

52 Week Range

28.440

Analysis Updated At

2026/01/26

PAVmed Inc (PAVM) is not a good buy for a beginner investor with a long-term strategy at this time. Despite the recent positive news regarding its subsidiary's contract with the Department of Veterans Affairs, the company's financial performance is extremely poor, with significant revenue and net income declines. Additionally, technical indicators and stock trends suggest further downside potential in the short to medium term. The lack of strong trading signals and weak options sentiment further reinforce a cautious approach.

Technical Analysis

The MACD is above 0 but positively contracting, RSI is neutral at 52.02, and moving averages are converging, indicating no clear trend. Key support levels suggest potential downside risk, with the next support at 5.874. Stock trend analysis indicates a 70% chance of a -4.51% decline in the next week and -14.01% in the next month.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Lucid Diagnostics, a subsidiary of PAVmed, secured a contract with the Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, which could enhance access for over 9 million veterans and potentially increase revenue in the future.

Neutral/Negative Catalysts

The stock has seen a significant decline of -16.58% in the regular market and an additional -6.19% in pre-market trading. Financial performance is extremely weak, with revenue down -99.50% YoY and net income down -109.84% YoY. Additionally, stock trend analysis suggests further downside potential.

Financial Performance

In Q3 2025, revenue dropped to $5,000, down -99.50% YoY. Net income fell to -$6,328,000, down -109.84% YoY. EPS decreased to -0.29, down -120.14% YoY. Gross margin improved to -1000, up 2032.65% YoY, but remains negative.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for PAVmed Inc.

1 Analyst Rating

Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 17 USD with a low forecast of 17 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 8.120

Low

Averages

High

Current: 8.120

Low

Averages

High

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$19 → $20

AI Analysis

2025-04-21

Reason